

ORIAHNN
(elagolix, estradiol, and norethindrone acetate)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age and older

Gender Female

Diagnosis

The patient must have the following:

Heavy menstrual bleeding associated with uterine leiomyomas (fibroids)

AND ALL of the following:

1. Patient is premenopausal
2. Pregnancy has been excluded
3. Medication is being prescribed by or in consultation with an obstetrician-gynecologist (OB-GYN)
4. Patient has **NOT** already used Myfembree or Oriahnn cumulatively for 24 months
5. **NOT** used in combination with Myfembree
6. Patient does **NOT** have current, or history of thrombotic or thromboembolic disorders and patient is not at increased risk for these events (e.g., women over 35 years of age who smoke or women with uncontrolled hypertension)
7. **NO** known liver impairment or disease (e.g., clinically significant elevated transaminases >2-3 times upper limit of normal, fibrosis F1-F4, etc.)
8. **NO** known osteoporosis
9. Prescriber agrees to monitor for suicidal ideation and mood disorders

Prior - Approval Limits

Quantity 168 capsules per 84 days

Duration 12 months

Prior – Approval *Renewal* Requirements

Age 18 years of age and older



**BlueCross
BlueShield**

Federal Employee Program.

ORIAHNN
(elagolix, estradiol, and norethindrone acetate)

Gender Female

Diagnosis

The patient must have the following:

Heavy menstrual bleeding associated with uterine leiomyomas (fibroids)

AND ALL of the following:

1. Documented improvement in patient's condition
2. Medication is being prescribed by or in consultation with an obstetrician-gynecologist (OB-GYN)
3. Patient has **NOT** already used Myfembree or Oriahnn cumulatively for 24 months
4. **NOT** used in combination with Myfembree
5. Patient does **NOT** have current, or history of thrombotic or thromboembolic disorders **AND** patient is not at increased risk for these events (e.g., women over 35 years of age who smoke or women with uncontrolled hypertension)
6. **NO** known liver impairment or disease (e.g., clinically significant elevated transaminases >2-3 times upper limit of normal, fibrosis F1-F4, etc.)
7. **NO** known osteoporosis
8. Prescriber agrees to monitor for suicidal ideation and mood disorders

Prior - Approval *Renewal* Limits

Quantity 168 capsules per 84 days

Duration 12 months – **One renewal ONLY**